The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXXIV.f

Opportunistic pulmonary/systemic infections

Publications

Gastaldi R, Sicaud A, Gaudin P, Baillet A

Pulmonary Pasteurellosis in a Patient Treated With Tocilizumab for Rheumatoid Arthritis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2017;23(8):451-452

Keyser FD

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Current rheumatology reviews. 2011;7(1):77-87

Hoshi D, Nakajima A, Inoue E, Shidara K, Sato E, Kitahama M, Seto Y, Tanaka E, Urano W, Ichikawa N, Koseki Y, Momohara S, Taniguchi A, Nishimoto N, Yamanaka H

Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.

Modern rheumatology. 2012;22(1):122-7